Aliano S, Cirmena G, Garuti A, Fugazza G, Bruzzone R, Rocco I, et al. HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22). Cancer Genet Cytogenet. 2007;177:115–9.

Article  PubMed  Google Scholar 

Andrieux J, Demory JL, Dupriez B, Quief S, Plantier I, Roumier C, et al. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer. 2004;39:82–7.

Article  PubMed  Google Scholar 

Etienne A, Carbuccia N, Adelaide J, Bekhouche I, Remy V, Sohn C, et al. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet Cytogenet. 2007;176:80–88.

Article  PubMed  Google Scholar 

Martin SE, Sausen M, Joseph A, Kingham BF, Martin ES. Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm. Cancer Genet. 2012;205:295–303.

Article  PubMed  Google Scholar 

Storlazzi CT, Albano F, Locunsolo C, Lonoce A, Funes S, Guastadisegni MC, et al. t(3;12)(q26;q14) in polycythemia vera is associated with upregulation of the HMGA2 gene. Leukemia. 2006;20:2190–2.

Article  PubMed  Google Scholar 

Ikeda K, Mason PJ, Bessler M. 3’UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood. 2011;117:5860–9.

Article  PubMed  PubMed Central  Google Scholar 

Ikeda K, Ogawa K, Takeishi Y. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms. Fukushima J Med Sci. 2012;58:91–100.

Article  PubMed  Google Scholar 

Harada-Shirado K, Ikeda K, Ogawa K, Ohkawara H, Kimura H, Kai T, et al. Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. Br J Haematol. 2015;168:338–49.

Article  PubMed  Google Scholar 

Chen CC, You JY, Lung J, Huang CE, Chen YY, Leu YW, et al. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. Haematologica. 2017;102:509–18.

Article  PubMed  PubMed Central  Google Scholar 

Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, et al. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Adv. 2017;1:1001–15.

Article  PubMed  PubMed Central  Google Scholar 

Odero MD, Grand FH, Iqbal S, Ross F, Roman JP, Vizmanos JL, et al. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia. 2005;19:245–52.

Article  PubMed  Google Scholar 

Cleynen I, Van de Ven WJ. The HMGA proteins: a myriad of functions (Review). Int J Oncol. 2008;32:289–305.

PubMed  Google Scholar 

Battista S, Fedele M, Secco L, Ingo AMD, Sgarra R, Manfioletti G. Binding to the other side: the AT-Hook DNA-binding domain allows nuclear factors to exploit the DNA minor groove. Int J Mol Sci. 2024;25:8863.

Parisi S, Piscitelli S, Passaro F, Russo T. HMGA proteins in stemness and differentiation of embryonic and adult stem cells. Int J Mol Sci. 2020;21:362.

Vignali R, Marracci S. HMGA genes and proteins in development and evolution. Int J Mol Sci. 2020;21:654.

Mansoori B, Mohammadi A, Ditzel HJ, Duijf PHG, Khaze V, Gjerstorff MF, et al. HMGA2 as a critical regulator in cancer development. Genes. 2021;12:269.

Khazem F, Zetoune AB. Decoding high mobility group A2 protein expression regulation and implications in human cancers. Discov Oncol. 2024;15:322.

Article  PubMed  PubMed Central  Google Scholar 

Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell. 1995;82:57–65.

Article  PubMed  Google Scholar 

Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet. 1995;10:436–44.

Article  PubMed  Google Scholar 

Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21:1025–30.

Article  PubMed  PubMed Central  Google Scholar 

Newman MA, Hammond SM. Lin-28: an early embryonic sentinel that blocks Let-7 biogenesis. Int J Biochem Cell Biol. 2010;42:1330–3.

Article  PubMed  Google Scholar 

Polesskaya A, Cuvellier S, Naguibneva I, Duquet A, Moss EG, Harel-Bellan A. Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency. Genes Dev. 2007;21:1125–38.

Article  PubMed  PubMed Central  Google Scholar 

Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41:843–8.

Article  PubMed  PubMed Central  Google Scholar 

Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi JL, et al. Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J Biol Chem. 2012;287:17386–97.

Article  PubMed  PubMed Central  Google Scholar 

Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I, et al. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget. 2012;3:1641–52.

Article  PubMed  PubMed Central  Google Scholar 

Lee YT, de Vasconcellos JF, Yuan J, Byrnes C, Noh SJ, Meier ER, et al. LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood. 2013;122:1034–41.

Article  PubMed  PubMed Central  Google Scholar 

de Vasconcellos JF, Fasano RM, Lee YT, Kaushal M, Byrnes C, Meier ER, et al. LIN28A expression reduces sickling of cultured human erythrocytes. PLoS ONE. 2014;9:e106924.

Article  PubMed  PubMed Central  Google Scholar 

Balzeau J, Menezes MR, Cao S, Hagan JP. The LIN28/let-7 pathway in cancer. Front Genet. 2017;8:31.

Article  PubMed  PubMed Central  Google Scholar 

Dutta A, Hutchison RE, Mohi G. Hmga2 promotes the development of myelofibrosis in Jak2(V617F) knockin mice by enhancing TGF-beta1 and Cxcl12 pathways. Blood. 2017;130:920–32.

Article  PubMed  PubMed Central  Google Scholar 

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.

Article  PubMed  PubMed Central  Google Scholar 

McGowan-Jordan J, Hastings RJ, More S. ISCN 2020: An International System for Human Cytogenomic Nomenclature. Karger AG; 2020.

Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol. 2002;119:558–66.

Article  PubMed  Google Scholar 

Zimran E, Tripodi J, Rampal R, Rappoport F, Zirkiev S, Hoffman R, et al. Genomic characterization of spleens in patients with myelofibrosis. Haematologica. 2018;103:e446–9.

Article  PubMed  PubMed Central  Google Scholar 

Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, et al. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell. 2020;78:477–492.e478.

Article  PubMed  PubMed Central  Google Scholar 

Li L, Kim JH, Lu W, Williams DM, Kim J, Cope L, et al. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022;139:2797–815.

Article  PubMed  PubMed Central  Google Scholar 

Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36:1769–70.

Article  PubMed  Google Scholar 

Benton CB, Tanaka M, Wilson C, Pierce S, Zhou L, Cortes J, et al. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res. 2015;39:419–23.

Article